21:28 , Nov 10, 2017 |  BC Week In Review  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop therapeutics to treat fibrotic liver disease using MiNA’s small activating RNA (saRNA) technology. The partners' deal is worth up to €307...
21:17 , Nov 10, 2017 |  BC Week In Review  |  Company News

Boehringer, Dicerna in deal to develop NASH candidates

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to discover and develop RNAi-based therapeutics to treat non-alcoholic steatohepatitis (NASH) using Dicerna's GalXC platform. Dicerna received $10 million upfront and is eligible for...
23:48 , Nov 8, 2017 |  BC Extra  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology in a deal worth up to €307 million ($355.7...
22:34 , Nov 2, 2017 |  BC Extra  |  Company News

Boehringer, Dicerna in deal to develop NASH candidates

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shot up $1.59 (28%) to $7.23 Thursday after it partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to discover and develop RNAi-based therapeutics to treat non-alcoholic steatohepatitis (NASH) using Dicerna's GalXC platform....